Authors


Robert Kleiman, MD

Latest:

The Benefits of Advanced Imaging Management Systems

How new technology can impact cardiac imaging in oncology clinical trials and have broader implications for patient safety.


Kathleen A. Mandziuk

Latest:

RBM in Late Phase

The reality of risk-based monitoring: history and successful implementation for late phase research.


Helen West

Latest:

Collaboration Planning

Sponsor-driven, CRO/recruitment provider collaborations propel cost-efficient study completion.


Neil Hawkins

Latest:

Health Technology Assessment in Clinical Development: When to Bridge Research and Decision-Making

Health technology assessment is a field of analysis that evaluates the medical, social, ethical, and economic implications of development, diffusion, and use of health technology.



Sergio Dalla Nora

Latest:

Three-Pronged Approach to Optimizing Trial Monitoring

Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.


Fran Ross

Latest:

TMF Reference Model Standard = Process Efficiency

One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.


Ashish Goel

Latest:

Driving Successful Clinical Trial Supply Management through Global Data Collaboration

An effective clinical trial is one of the most crucial stages in the creation of a new drug.



Philip E. Doren

Latest:

Impact on the Future

The use of RBM may be the only way forward as long as the development of medicines relies on clinical testing.


Ivana Furimsky

Latest:

Developing a Successful Peer-to-Peer Mentoring Program

Clinical research organizations should look to peer-to-peer mentoring for professional development.


Michael R. Hamrell

Latest:

Three-Pronged Approach to Optimizing Trial Monitoring

Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.


Mark Penniston

Latest:

2020 Vision: Fulfilling the Future of Clinical Research

IntroductionAfter decades of promise, we have begun to realize the fruit of “-omics” technology. Recent advances in proteomics, genomics and metabolomics have enabled us to understand the molecular basis of disease at both the diagnostic and treatment levels. Equally important, a growing suite of biomarkers now provides predictive value for diagnosis, disease progression and cure/remission.


Michael J. Howley, PA-C, MBA, PhD

Latest:

Getting to Clinical Trial Diversity

Differing levels of trust in clinical trials information channels across diverse populations is examined in this research.


Karen Redding

Latest:

TMF Reference Model Standard = Process Efficiency

One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.


Lesly Atlas

Latest:

Linking Leaders: Beyond the Boardroom

A view on redefining key roles across the evolving clinical development landscape.


Michael Christel

Latest:

Next-Generation Focus in Immuno-Oncology

How one biotech is tackling the unmet need for additional immunotherapies and combination approaches in cancer.


Judith M. Schloss Markowitz

Latest:

Three-Pronged Approach to Optimizing Trial Monitoring

Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.


Chitra Lele

Latest:

Measurement and Analysis of Patient-Reported Outcomes to Provide the 'Patient Voice'

Clinical trials today are more commonly assessing quality of life and other PRO measures as part of post-approval studies to present evidence on treatment effectiveness. It is crucial, therefore, that clinical teams have a strong plan for the capture and analysis of PROs data, and the resources required to draw clinically meaningful extrapolations.


Lee S. Scheible

Latest:

Developing a Logical Sourcing Strategy

The four essential steps to ensuring optimal clinical deliverable specifications and process controls.


Dat Nguyen

Latest:

RBM in Late Phase

The reality of risk-based monitoring: history and successful implementation for late phase research.


Moe Alsumidaie

Latest:

Preserving Sight: A Deep Dive into ONL Therapeutics' Innovative Approach to Combat Retinal Diseases

In this Q&A, David Esposito, CEO of ONL Therapeutics provides a glimpse into the company's mission, challenges, and strategies associated with clinical trials.


Gary Coward

Latest:

Shifting the Large Simple Trials Paradigm

Conducting Large Simple Trials to answer questions about "real-world" medical interventions is not a recent concept.



Thomas Santarelli

Latest:

Sustaining Innovation

Constant technological advancements continue to alter the compliance battle.


Michael Henning

Latest:

Maximizing Oncology Imaging Data

Increasing development costs and high failure rates require earlier integration of imaging data in the Phase I setting.


John Humphreys

Latest:

Cracking the Code on Study Start-Up

No matter how long you?ve been in the clinical trials business, the mantra is always the same: not enough investigators, not enough patients, enrollment falling behind, need for rescue sites, study budget overspend.


Prasad Sristi

Latest:

Why are CRO Profits Shrinking While the Industry is Growing By Leaps And Bounds?

The pharmaceutical industry continues to outsource more clinical trials to contract research organizations each year...



Emily Cantrell

Latest:

5 Challenges in Site/CRO Relationships

Strong working relationships between clinical trials sites and the CRO managing the study are critical to successfully executing a clinical trial.

© 2024 MJH Life Sciences

All rights reserved.